An Act to amend and reenact § 32.1-276.7:1 of the Code of Virginia and to amend the Code of Virginia by adding in Title 32.1 a chapter numbered 7.3, consisting of sections numbered 32.1-276.12, 32.1-276.13, and 32.1-276.14, and by adding in Article 1 of Chapter 34 of Title 54.1 a section numbered 54.1-3431.1, relating to prescription drug affordability advisory panel established; maximum fair price; annual reports; civil penalties.
HB483 is a broad prescription drug affordability measure that expands Virginia’s All-Payer Claims Database and creates a new Prescription Drug Affordability Advisory Panel. The bill directs the Department of Health and the Bureau of Insurance to collect paid claims and non-claims payment data from a wide range of payers, including insurers, third-party administrators, Medicaid, state and local plans, and certain federal plans where permitted. It also establishes detailed rules for data privacy, data release, public reporting, advisory oversight, and annual reporting on prescription drug price increases, rebates, and high-cost drugs.
The bill further creates a new chapter in the Code of Virginia, the Affordable Medicine Act, to study prescription drug pricing and recommend policy changes. The new panel would meet quarterly, publish quarterly updates, and submit annual reports on drug price trends, patient out-of-pocket costs, rebate and discount transparency, Medicaid savings opportunities, and other affordability strategies. In addition, the bill adds a new section governing “maximum fair prices” for certain prescription drugs, tying Virginia reimbursement and payment rules to federal maximum fair price determinations and requiring savings to be passed through to consumers where possible.
HB483 would significantly expand state health-data infrastructure by broadening the Virginia All-Payer Claims Database, creating new advisory and data-release bodies, and authorizing civil penalties for private data suppliers that fail to report required information. It would also affect insurers, pharmacy benefits managers, employers with ERISA plans that opt in, health care providers, manufacturers, and wholesalers by imposing new reporting, transparency, and reimbursement-related obligations. The bill amends §§ 32.1-276.3 and 32.1-276.7:1 and adds new provisions in Title 32.1 and § 54.1-3431.1, with the latter section designed to regulate payment for certain prescription drugs and to enforce consumer-oriented savings pass-through requirements.
The bill appears to have been framed as a consumer affordability and transparency measure, with its structure emphasizing data collection, oversight, and lower prescription drug costs. The inclusion of annual and quarterly reporting, public analyses, and consumer cost-sharing priorities suggests a policy goal of improving accountability in drug pricing and health spending. However, the fact that the bill was vetoed by the Governor indicates that, despite its affordability rationale, it did not ultimately receive executive approval.
The most notable points of contention are likely to have centered on the bill’s new price-control and reporting requirements for prescription drugs, especially the section limiting payment to a “maximum fair price” and authorizing civil penalties for manufacturers that withdraw drugs to avoid the law. The bill also raises potential concerns for pharmacy benefits managers, insurers, and employers about disclosure of financial information, the scope of data submission, and the handling of ERISA plans. Another likely issue is the balance between transparency and confidentiality, since the bill requires extensive data collection while also restricting public disclosure of provider-specific and carrier-specific reimbursement information.